Atrophic vaginitis
Conditions
Interventions
This is a controlled clinical study with two arms. Genitourinary Syndrome of Menopause (GSM) will be evaluated in postmenopausal women before and after vaginal laser treatment (one session every 30 da
Sponsors
Hospital de Clínicas de Porto Alegre
Hospital de Clínicas de Porto Alegre
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Healthy postmenopausal women (at least 12 months since their last menstrual period, or with bilateral oophorectomy, or hysterectomized with follicle-stimulating hormone higher than 40 U/L; estradiol lower than 25 pg/mL); negative oncotic colpocytology within the last year; who agree to participate in the study and sign the informed consent form (ICF)
Exclusion criteria
Exclusion criteria: Active or recent (<15 days) vaginal lesions; use of hormone replacement therapy in the last 6 months; untreated genitourinary tract infections; abnormal uterine bleeding; history of photosensitivity disorder or use of photosensitizing drugs; grade II-III genital prolapse (according to the Pelvic Organ Prolapse Quantification system, POP-Q); bacterial or viral vaginal infection (HPV, Herpes); immunosuppression; chronic corticosteroid use; scleroderma; extensive prior radiotherapy; burns in the area; collagen disorders; pregnancy and breastfeeding; genital neoplasia; anticoagulant therapy; patients with sling/mesh; uncontrolled diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| An improvement in the symptoms of Genitourinary Syndrome of Menopause (GSM) is expected, assessed through standardized questionnaires on quality of life and intimate well-being, as well as morphometric analysis of the vaginal mucosa. Data will be collected before the start of treatment and three months after the intervention. | — |
Countries
Brazil
Contacts
Public ContactEdison Capp
Hospital de Clínicas de Porto Alegre
Outcome results
None listed